It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ: EDIT) have collapsed by about 88% over the past three years despite recent positive news regarding its experimental therapies and intellectual property.

Editas is driving its first CRISPR-based therapy toward commercialization. Following approval of a similar treatment from CRISPR Therapeutics and partner Vertex Pharmaceuticals in December, its chances of achieving commercialization appear better than ever.

Is Editas Medicine a good investment following the approval of the first CRISPR-based drug? Let's weigh its strengths against the challenges it faces to find out.

Continue reading

Source Fool.com